2. Plus GE, Brower AJ, Clagett OT: Chronic constrictive pericarditis: Roentgenologic findings in 35 surgically proven cases. Proc Staff Meet Mayo Clin 1957;32:555 Reply Dr. Mantri and colleagues argue that because the left atrial to aorta ratio in their patients with constrictive pericarditis was higher than we reported,' limitation of atrial distension is not a feature of constrictive pericarditis and therefore cannot contribute to the pathogenesis of edema in these patients.
Reply
Dr. Mantri and colleagues argue that because the left atrial to aorta ratio in their patients with constrictive pericarditis was higher than we reported,' limitation of atrial distension is not a feature of constrictive pericarditis and therefore cannot contribute to the pathogenesis of edema in these patients.
We found that the left atrial to aorta ratio in our patients with constrictive pericarditis (1.29; SEM, 0.04) was lower than that in patients with congestive heart failure (1.8; SEM, 0.14) with similar elevation of atrial pressures. This does not imply that the atria in patients with constrictive pericarditis do not dilate. It only suggests that patients with constrictive pericarditis have less distended atria in comparison with patients who have congestive heart failure. We argued that this limitation of atrial distension may explain the substantially lower levels of circulating atrial natriuretic peptide found in these patients. The relatively low levels of atrial natriuretic peptide in constrictive pericarditis probably explain the greater salt and water accumulation that occurs in this condition. These findings are, therefore, consistent with the suggestion that limitation of atrial distension contributes to fluid retention in constrictive pericarditis, and this hypothesis is not challenged by the findings of Mantri et al.
There is other evidence to suggest that atrial distension is limited by constrictive pericarditis: Wolozin et a12 showed that in patients with constrictive pericarditis, relief of atrial constriction during pericardiectomy caused an immediate increase in atrial natriuretic peptide, although during this period, the left and right atrial pressures were decreasing. This "paradoxical" response is explained by the increased atrial stretch permitted by stripping the pericardium.
plasma hormones before and after pericardiectomy. Circulation 2. Wolozin MW, Ortola FV, Spodick DH, Seifter JL: Release of atrial natriuretic factor after pericardiectomy for chronic constrictive pericarditis. Am J Cardiol 1988;62:1323-1325
Effects of Digitalis and Dobutamine
The data presented in the recent article by Schobel et al (Contrasting Effects of Digitalis and Dobutamine on Baroreflex Sympathetic Control in Normal Humans: Circulation 1991;84:1118-1129) do not appear to support the conclusion drawn regarding an effect of digitalis on sympathetic activation during baroreceptor unloading.
Muscle sympathetic nerve activity (MSNA) expressed as bursts per minute increased by 8 units during lower body negative pressure (LBNP) without drug and by 10 units during Cedilanid. With dobutamine, the increase was 7 units versus 10 during control. The results using units per minute were similar: increases of 187 during control LBNP and 190 after Cedilanid, 275 during the control period before dobutamine and 202 after drug.
Clearly, there is no potentiation of the sympathetic response to LBNP by Cedilanid, much less any difference between Cedilanid and dobutamine. The inference of an effect of Cedilanid must come from the analysis of "percent changes" (shown in Figure 3 ), because baseline values for MSNA before Cedilanid and dobutamine were lower than control. There is, however, little a priori or empiric justification for assuming that a given increase in MSNA represents a different degree of sympathetic activation just because baseline values differ. The phenomenon of rapid baroreceptor resetting in fact makes changes from a lower baseline induced by the pressor and inotropic effects of these drugs likely to represent exactly the same degree of activation during a second stimulus. Even if one accepted percent changes as a valid measure, the crucial statistical comparison would be a factorial ANOVA comparing the changes during Cedilanid with those during vehicle and dobutamine. This was not provided, and inspection of Figure 3 suggests little chance of a statistically significant or biologically meaningful between-day difference in the Cedilanid and dobutamine responses.
Overall, this seems to be a study that, although well designed and executed, does not support meaningful baroreceptor sensitization by digitalis in normal humans, at least during a modest baroreceptor unloading stimulus. 
Reply
As noted in the article, the muscle sympathetic nerve activity (MSNA) responses to lower body negative pressure (LBNP) were significantly augmented after Cedilanid-D when expressed as bursts per minute and units per minute as well as when expressed as percent change from control using repeated-measures ANOVA Cedilanid-D decreased baseline MSNA. However, dobutamine also decreased baseline MSNA. Despite similar decreases in baseline MSNA with Cedilanid-D and dobutamine, we observed that Cedilanid-D augmented the MSNA responses to LBNP, whereas dobutamine did not increase the MSNA responses when expressed as either absolute units or percent change. Therefore, we concluded that Cedilanid-D augmented the MSNA responses to LBNP and that this could not be accounted for by the decrease 1991;83:1880-1887 in baseline MSNA after Cedilanid-D.
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In his letter, Dr. Goldsmith states that "the phenomenon of rapid baroreceptor resetting in fact makes changes from a lower baseline induced by the pressor and inotropic effects of these drugs likely to represent exactly the same degree of activation during a second stimulus." This statement may be unfounded because it assumes that observations regarding baroreceptor resetting are synonymous with baroreflex control of sympathetic nerve activity. The concept of acute baroreceptor resetting would hold that with a sustained increase in arterial pressure, the initial reflex decrease in MSNA would not be sustained. In contrast to these predictions, we have found in separate studies in our laboratories that prolonged (30-minute) increases in arterial pressure caused by infusion of phenylephrine produce sustained decreases in MSNA. Indeed, after cessation of phenylephrine, MSNA remained below control levels for several minutes even after arterial pressure and central venous pressure had returned to control.1 Similar observations have been made in rats by Undesser et a12 and by Kenney et al. 3 Thus, we have not found that the phenomenon of acute baroreceptor resetting in animals is overtly manifest in baroreflex control of MSNA in humans. Accordingly, we question the implication that the phenomenon of acute baroreceptor resetting should have been considered in interpreting our results.
As clearly demonstrated in Figures 2 and 3 , as well as in Tables 1 and 2, LBNP produced nearly identical reductions in central venous pressure (unloading cardiopulmonary baroreceptors) before and after drug administration in the digitalis, dobutamine, and placebo treatment groups. However, the magnitude of the increase in MSNA during LBNP was significantly potentiated only by Cedilanid-D and was not altered by dobutamine or placebo (Figure 3 , repeated-measures ANOVA). These findings are clearly consistent with a potentiation of cardiopulmonary baroreflex regulation of sympathetic nerve activity after digitalis, without such potentiation after dobutamine or placebo. These data are consistent with the observation in prior human and animal studies that digitalis potentiates baroreflex mechanisms, most probably through an afferent mechanism.
Clinical Restenosis Trials: A Perspective From the Pharmaceutical Industry
In their recent editorial, Popma et a1l outlined criteria and put forth various suggestions for the conduct of clinical restenosis trials. We have recently incorporated many of these points into an ongoing multicenter study of the angiotensin converting enzyme (ACE) inhibitor quinapril in a 3-year follow-up of clinical ischemic events in a population of patients after angioplasty. The Quinapril Isch-emic Event Trial (QUIET) is a double-blind, parallel-group, placebo-controlled multicenter study of 1,700 patients treated with quinapril or placebo for 3 years. The primary end points of cardiac death, myocardial infarction, coronary artery bypass grafting, repeat angioplasty, and hospitalization for unstable angina will be complemented with angiographic data from a subgroup of 500 patients. In view of the suggestions of Drs. Popma, Califf, and Topol, QUIET is remarkable for its use of "hard" clinical end points, minimal exclusions, and a primary analysis based on intent to treat. In addition, the sample size provides adequate power for both early (up to 6 months, presumed to reflect restenosis) and late events (6-36 months, presumed to reflect progression of disease).
We found the article to be both timely and informative but felt that the authors' suggestion of a stepwise progression from preliminary preclinical experiments through pilot efficacy studies to a major intervention trial was open to comment. Although such a strategy may appear to be fiscally and scientifically responsible, we would point out that pilot studies with small patient numbers are unlikely to result in any useful efficacy data in terms of clinical end points; any information gained in such studies is likely to relate primarily to short-term safety. All too often, inadequately powered pilot studies are published, and credence is given to the results. It is of more value in the long term to the medical community to bypass the periphery of inconclusive investigations and test the primary hypothesis in a definitive trial. For example, it has been subsequently acknowledged that the Cardiac Arrhythmia Pilot Study (CAPS) ". _could not possibly be expected to detect even large mortality differences between such small groups with statistical certainty."2 The answer came only with the definitive Cardiac Arrhythmia Suppression Trial (CAST).
Small Trials and New Therapies
We appreciate the complementary letter from Uprichard and colleagues about our point of view on clinical trials. They have raised the critical issue, however, of the methods that should be used in bringing a new therapy into the final phases of evaluation. In our editorial comment, we suggested that large clinical trials with adequate power should proceed only after careful smaller studies are completed demonstrating convincing evidence of physiological activity that would be consistent with a beneficial clinical effect. Uprichard and colleagues seem to prefer to bypass this step in favor of moving directly to large clinical trials.
The past several years have been a time in which cardiologists should have developed substantial humility about widespread application of therapies based on small trials designed to reinforce pathophysiological reasoning. Examples of widely accepted therapies that proved to be detrimental when applied to the true test include antiarrhythmic agents for nonsustained ventricular arrhythmias, calcium channel blockers for patients with poor left ventricular function, and possibly prophylactic lidocaine. Thus, we agree with Uprichard that small studies cannot be used to substitute for larger trials.
Our contention, however, is that the smaller trials, if portrayed correctly in the literature, provide building blocks upon which
